期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 137, 期 2, 页码 240-247出版社
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPGA95KVSAUDMF
关键词
PRAME; Preferentially expressed antigen of melanoma; Mullerian carcinoma; Malignant mesothelioma; Serous effusions; Diagnosis; Quantitative real-time PCR; Western blotting
类别
资金
- Norwegian Cancer Society
- Research Foundation at the Norwegian Radium Hospital
- Inger and John Fredriksen Foundation for Ovarian Cancer Research, Oslo, Norway
The FRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. The objective of this study was to validate this finding at the messenger RNA (mRNA) and protein levels. Quantitative real-time polymerase chain reaction analysis of 126 mullerian carcinomas and 23 malignant mesotheliomas showed significantly higher PRAME mRNA expression in the former tumor (P < .001, test sensitivity and specificity, 89% and 91%, respectively). PRAME protein was expressed in 41 of 50 mullerian carcinomas and 0 of 30 mesotheliomas using Western blotting (P < .001; test sensitivity and specificity, 82% and 100%, respectively). PRAME levels in mullerian carcinoma were unrelated to survival; however, PRAME protein expression was up-regulated in solid metastases compared with primary carcinoma and effusions (P < .001). Our data confirm that PRAME effectively differentiates mullerian carcinoma from malignant mesothelioma at the mRNA and protein levels, suggesting a role in the diagnostic workup of serosal cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据